Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > TOP STORIES
TOP STORIES
-
REGULATORY Japan to Announce New Drug Prices on March 5
February 15, 2024
-
REGULATORY Chuikyo Issues 2024 Reform Recommendation; 1,000 Yen Premium Set for Inpatient Biosimilar Use
February 14, 2024
-
REGULATORY Japan Approves Jardiance for CKD, Label Expansion for Opdivo and More
February 13, 2024
-
BUSINESS Medac Poised to Cement Japan Foothold in RA, Eyes Rare Disease Launch Too: CEO
February 9, 2024
-
BUSINESS Mounjaro Logs 5.6 Billion Yen in Q3 YTD despite Curbed Shipments: Mitsubishi
February 8, 2024
-
REGULATORY Generic Panel to Issue Report in Spring-Summer to Drive Manufacturing Efficiency towards Stable Supplies: Official
February 8, 2024
-
REGULATORY Legal Changes on Horizon for GMP Inspection Authorities, Other Regulation Panel Topics?
February 7, 2024
-
BUSINESS 2,000 Patients Receiving Leqembi in US, 4 Times the Number on Wait List: Eisai
February 7, 2024
-
REGULATORY AMED Needs More Manpower to Fulfill Its Role as Funding Agency: President
February 6, 2024
-
BUSINESS Sumitomo to Reinforce Restructuring to Fight Deficit, First in North America: President
February 6, 2024
-
REGULATORY Truvada Clears Preliminary Review for PrEP Use, but Coverage Not Granted
February 6, 2024
-
REGULATORY Will Truvada Win Health Coverage as Japan’s First Drug for HIV Prevention?
February 5, 2024
-
BUSINESS Chugai’s 2023 Earnings Slip as Ronapreve Wanes, but Sales Still Top 1 Trillion Yen
February 2, 2024
-
REGULATORY Japan to Introduce Fee Premium for Inpatient Biosimilar Use, Covering 13 APIs
February 1, 2024
-
BUSINESS Sumitomo to Cut Med- to Long-Term Guidance amid Tepid Uptake of New Drivers
February 1, 2024
-
REGULATORY Japan to Revise Ad Guidelines to Address GLP-1 Use for Cosmetic Weight Loss
January 31, 2024
-
COMMENTARY Is Case of Leqembi a “Steppingstone” to New CEA Price Adjustment Rule? Pharma Industry on Guard
January 30, 2024
-
REGULATORY MHLW to Require Pharma to Disclose More Categories of Physician Payments under Clinical Trials Act
January 30, 2024
-
REGULATORY Chuikyo to Discuss Exclusion of Long-Listed Biologics from New Coverage Scheme
January 29, 2024
-
REGULATORY Break-Up of LDP Factions Won’t Have Major Impact on Pharma Policy, but Could Make Lobbying Tougher
January 26, 2024
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…